Boston Scientific Receives FDA Approval For The Vercise Genus(TM) Deep Brain Stimulation System

Fourth-generation DBS portfolio features full-body MR conditional devices MARLBOROUGH, Mass., Jan. 22, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) appr... Devices, Neurology, FDA Boston Scientific, Vercise Genus, Deep Brain Stimulation, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news